Acute and chronic effects of gepirone and fluoxetine in rats tested in the elevated plus-maze: An ethological analysis

Pharmacology Biochemistry and Behavior

Volumn 65, Issue 2, 2000, Pages 209-216

  Silva, R C B ^a   Brandao M L ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Elevated plus maze; Ethological analysis; Fluoxetine; Gepirone; Rat Thigmotaxis

Indexed keywords

FLUOXETINE; GEPIRONE; SEROTONIN; SEROTONIN 1A AGONIST; SEROTONIN UPTAKE INHIBITOR;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG CLASSIFICATION; DRUG EFFECT; ETHOLOGY; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RAT; RISK ASSESSMENT; TRANQUILIZING ACTIVITY;

ANIMALS; ANXIETY; EXPLORATORY BEHAVIOR; FLUOXETINE; MALE; PYRIMIDINES; RATS; RATS, WISTAR; SEROTONIN AGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 0033976134     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(99)00193-8     Document Type: Article

References (40)

1. Anseloni V., Brandão M.L. Behavioral and pharmacological validation of the elevated plus maze constructed with transparents walls. Braz. J. Med. Biol. Res. 28:1995;597-601.
2. Anseloni V., Brandão M.L. Ethopharmacological analysis of behaviour of rats using variations of the elevated plus-maze. Behav. Pharmacol. 8:1997;533-540.
3. Blanchard D.C., Blanchard R.J., Rodgers R.J. Risk assessment and animal models of anxiety. Olivier B., Mos J., Slangen J.L. Animal models in psychopharmacology. 1991;117-134 Birkhauser, Bale.
4. 1A agonist gepirone. Electrophysiological studies in the rat brain Synapse. 1:1987;470-480.
5. Blier P., De Montigny C., Chaput Y. Modifications of the serotonin system by antidepressant treatments. Implications for the therapeutic response in major depression J. Clin. Psychopharmacol. 7:1987;24-35.
6. Cole J.C., Rodgers R.J. An ethological analysis of the effects of chlordiazepoxide and bretazenil (Ro 16-6028) in the murine elevated plus-maze. Behav. Pharmacol. 4:1993;573-580.
7. Cole J.C., Rodgers R.J. Ethological evaluation of the effects of acute and chronic buspirone treatment in the murine elevated plus-maze test. Comparison with haloperidol Psychopharmacology (Berlin). 114:1994;288-296.
8. Cruz A.P., Graeff F.G. Ethopharmacological analysis of rat behavior on the elevated plus-maze. Pharmacol. Biochem. Behav. 49:1994;171-176.
9. 1A receptors. Stahl S.M., Hesselink J.M.K., Gastpar M., Traber J. Serotonin 1A receptors in depression and anxiety. 1992;35-54 Raven Press, New York.
10. Graeff F.G. Serotonergic systems. Psychiatr. Clin. Nor. Am. 20:1997;723-739.
11. Griebel G. 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders. More than 30 years of research Pharmacol. Ther. 65:1995;319-395.
12. Griebel G., Sanger D.J., Perrault G. The use of the rat elevated plus-maze to discriminate between non-selective and BZ-1 (w1) selective, benzodiazepine receptor ligands. Psychopharmacology (Berlin). 124:1996;245-254.
13. Griebel G., Rodgers R.J., Perrault G., Sanger D.J. Risk assessment behaviour. Evaluation of utility in the study of 5-HT-related drugs in the rat elevated plus-maze test Pharmacol. Biochem. Behav. 57:1997;817-827.
14. Handley S.L., Mithanim S. Effects of alpha-adrenoceptor agonist and antagonists in a maze-exploration model of "fear"-motivated behaviour. Naunyn Schmiedebergs Arch. Pharmacol. 327:1984;1-5.
15. Handley S.L., Mc Blane J.W. Opposite effects of fluoxetine in two animal models of anxiety. Br. J. Pharmacol. 107:1993;446P.
16. Handley S.L., Mc Blane J.W. 5-HT drugs in animal models of anxiety. Psychopharmacology (Berlin). 112:1993;13-20.
17. 1A agonist 8-OH-DPAT stimulations rat motor activity. Eur. J. Pharmacol. 160:1989;303-307.
18. 1A autoreceptors and the mode of action of selective serotonin reuptake inhibtors (SSRI). Behav. Brain Res. 73:1996;281-283.
19. Hog S. A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacol. Biochem. Behav. 54:1996;21-30.
20. Kshama D., Munonyedi U. Modulation of baseline behavior in rats by putative serotonergic agents in three ethoexperimental paradigms. Behav. Neural. Biol. 54:1990;234-253.
21. Lister R.G. Ethologically-based animal models of anxiety disorders. Pharmacol. Ther. 46:1990;321-340.
22. 1A receptor activation on the anxiogenic effects induced by isolation in the elevated plus-maze test. Physiol. Behav. 54:1993;753-758.
23. Montgomery K.C. The relationship between fear induced by novel stimulation and exploratory behaviour. J. Comp. Physiol. Psychol. 48:1955;254-260.
24. 1A receptors: Possible clinical relevance. In: Langer, S. Z.; Brunello, N.; Racagni, G.; Mendlewicz, J., eds. Serotonin receptor subtypes: Pharmacological significance and clinical implications, vol. 1. Basel: Karger, 1992:80-88.
25. 1A receptors on the exploratory activity of rats in the elevated plus-maze. Psychopharmacology (Berlin). 107:1992;135-139.
26. 2C serotonin receptors by fluoxetine (Prozac). Pharmacology. 94:1997;2036-2040.
27. Nutt D.J., Glue P. Imipramine in panic disorder. Clinical response and pharmacological changes J. Psychopharmacol. 5:1991;56-64.
28. Pellow S., Chopin P., File S.E., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods. 14:1985;149-167.
29. Pellow S., File S.E. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze. A novel test of anxiety in the rat Pharmacol. Biochem. Behav. 24:1986;525-529.
30. Rodgers R.J., Cole J.C., Cobain M.R.et al. Anxiogenic-like effects of fluprazine and eletroprazine in the mouse elevated plus-maze. Profile comparisons with 8-OH-DPAT, CGS 12066B, TFMPP and mCPP Behav. Pharmacol. 3:1992;621-634.
31. 3 receptors antagonists, ondansetrom and WAY 100,289, in the murine plus-maze. Br. J. Pharmacol. 110:1993;12P.
32. Rodgers R.J., Cole J.C. The elevated plus-maze. Pharmacology, methodology and ethology Cooper S.J., Hendrie C.A. Ethology and psychopharmacology. 1994;9-44 Wiley, Chichester.
33. Rodgers R.J., Johnson N.J.T. Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety. Pharmacol. Biochem. Behav. 52:1995;297-303.
34. Rodgers R.J., Cao B.J., Dalvi A., Holmes A. Animal models of anxiety. An ethological perspective Braz. J. Med. Biol. Res. 30:1997;289-304.
35. Setem J., Pinheiro A.P., Motta V.A., Morato S., Cruz A.P.M. Ethopharmacological analysis of 5-HT ligand on the rat elevated plus-maze. Pharmacol. Biochem. Behav. 62:1999;515-521.
36. Treit D., Fundytus M. Thigmotaxis as a test for anxiolytic activity in rats. Pharmacol. Biochem. Behav. 31:1988;958-962.
37. 3 antagonists and benzodiazepines. Their comparative behavioural pharmacology. Chichester, UK: John Wiley & Sons; 1991;107-131.
38. Treit D., Menard J., Royan C. Anxiogenic stimuli in the elevated plus-maze. Pharmacol. Biochem. Behav. 44:1993;463-469.
39. Tricklebank M.D., Forler C., Middlemiss D.N., Fozard J.R. Subtypes of the 5-HT receptor mediating the behavioural responses to 5-methoxy-N,N-dimethyltryptamine in the rat. Eur. J. Pharmacol. 117:1985;15-24.
40. Trullas, R.; Skolnick, P.: Are glutamatergic pathways involved in the pathophysiology of anxiety? In: Briley, M.; File, S., eds. New concepts in anxiety. London: Macmillan; 1991:382-394.